Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion (Q42879201)

9 November 2017

0 references

Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion (English)

1 reference

9 November 2017

1 reference

myelodysplastic syndrome

1 reference

Martin Jädersten

1 reference

9 November 2017

1 March 2010

1 reference

9 November 2017

1 reference

9 November 2017

1 reference

9 November 2017

1 reference

9 November 2017

348-351

1 reference

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome

9 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

SPARC and tumor growth: where the seed meets the soil?

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Targeted therapies in myelodysplastic syndrome.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

The evolution of thalidomide and its IMiD derivatives as anticancer agents

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833060

Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes

16 August 2018

1 reference

12 December 2020

Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level

1 reference

12 December 2020

Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome

1 reference

12 December 2020

Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome

1 reference

12 December 2020

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

1 reference

12 December 2020

10.3324/HAEMATOL.2009.019141

Identifiers

DOI

1 reference

9 November 2017

1 reference

PMC publication ID

2833060

9 November 2017

PubMed publication ID

20207839

1 reference

PMC publication ID

2833060